Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NervGen Pharma ( (NGEN) ) has shared an announcement.
On May 21, 2026, NervGen Pharma announced it had commenced an underwritten public offering of common shares, pre-funded warrants and accompanying common share warrants, with all securities to be sold by the company and closing subject to customary conditions. The financing is intended to bolster NervGen’s cash resources to advance NVG-291 through clinical studies and support general corporate and working capital needs, a move that could be pivotal for sustaining development of its neuroreparative pipeline and reinforcing its position in the competitive neurology-focused biotech sector.
The offering is being conducted via a Canadian base shelf prospectus and an effective U.S. shelf registration statement on Form F-10 under the Multijurisdictional Disclosure System, with final pricing terms to be disclosed in a forthcoming prospectus supplement. Leerink Partners and TD Cowen are acting as joint bookrunning managers, underscoring institutional capital markets support as NervGen seeks to secure sufficient funding to navigate the costly and uncertain clinical development pathway for NVG-291 and related programs.
The most recent analyst rating on (NGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the NGEN Stock Forecast page.
More about NervGen Pharma
NervGen Pharma Corp. is a Vancouver-based, clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, a subcutaneously administered peptide targeting the CSPG-PTPσ pathway, holds U.S. Fast Track and EU Orphan Drug designations for spinal cord injury, and is complemented by a next-generation program, NVG-300.
Average Trading Volume: 174,358
Technical Sentiment Signal: Buy
Current Market Cap: $302.7M
Learn more about NGEN stock on TipRanks’ Stock Analysis page.